{
  "meta": {
    "title": "Leukemia",
    "url": "https://brainandscalpel.vercel.app/leukemia-01c4f1e2.html",
    "scrapedAt": "2025-11-30T08:49:09.281Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">t(8;14) involving MYC gene</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">t(9;22) involving BCR-ABL1</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">t(15;17) involving PML-RARA</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">t(11;14) involving cyclin D1</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old male with a history of fatigue and splenomegaly is diagnosed with Chronic Myeloid Leukemia (CML) in the chronic phase. Which chromosomal abnormality is pathognomonic for this disease?</span></p>",
      "unique_key": "DT1295284",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295284,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The Philadelphia chromosome (t(9;22)) creates the BCR-ABL1 fusion gene, which is responsible for the pathogenesis of CML.</li>\r\n<li>t(8;14) is associated with Burkitt lymphoma.</li>\r\n<li>t(15;17) is linked to Acute Promyelocytic Leukemia (APL).</li>\r\n<li>t(11;14) is found in Mantle Cell Lymphoma.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>The Philadelphia chromosome is the hallmark of CML and a key diagnostic feature.</p>\r\n ",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Lymphocytic Leukemia (CLL)</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Hodgkin Lymphoma (HL)</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Diffuse Large B-Cell Lymphoma (DLBCL)</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Follicular Lymphoma (FL)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old female presents with fever, weight loss, and night sweats. Bone marrow biopsy shows Reed-Sternberg cells. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295285",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295285,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Reed-Sternberg cells are characteristic of classical Hodgkin Lymphoma.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501085acb6d4e-70d4-4f49-a972-cb4e00c627a0.jpg\">\r\n<ul>\r\n<li>CLL and FL do not have Reed-Sternberg cells.</li>\r\n<li>DLBCL can have large atypical cells but lacks the classic Reed-Sternberg cell morphology.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Presence of Reed-Sternberg cells in lymphoid tissue is diagnostic for Hodgkin Lymphoma.</p>\r\n ",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">t(15;17)</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">t(8;21)</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">del(5q)</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">t(11;14)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old patient with newly diagnosed Acute Myeloid Leukemia (AML) presents with Auer rods on peripheral blood smear. Which genetic abnormality is most likely associated with this finding?</span></p>",
      "unique_key": "DT1295286",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295286,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Auer rods are often associated with AML with t(8;21), which involves RUNX1-RUNX1T1 fusion.</li>\r\n<li>t(15;17) is associated with APL.</li>\r\n<li>del(5q) is related to myelodysplastic syndromes.</li>\r\n<li>t(11;14) is linked to Mantle Cell Lymphoma.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010881a4387b-680d-4bf4-9249-03a8cc3a5f75.jpg\">\r\n<p><strong>Key Takeaways: </strong>Auer rods are a hallmark of AML and are particularly seen in subtypes with specific genetic abnormalities like t(8;21).</p>\r\n ",
      "correct_choice_id": 22,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">del(17p)</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">del(13q)</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Trisomy 12</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">del(11q)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old male with CLL presents with progressive anemia and increased lymphocyte count. Which of the following cytogenetic abnormalities is associated with a good prognosis in CLL?</span></p>",
      "unique_key": "DT1295287",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295287,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>del(13q) is associated with a favorable prognosis in CLL.</li>\r\n<li>del(17p) involves TP53 deletion and indicates poor prognosis.</li>\r\n<li>Trisomy 12 and del(11q) are associated with intermediate and poor prognosis, respectively.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Prognosis in CLL is highly influenced by the presence of specific cytogenetic abnormalities, with del(13q) being favorable.</p>\r\n",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and R are true, and R is the correct explanation of A</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and R are true, but R is not the correct explanation of A</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">A is true, but R is false</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">A is false, but R is true</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Assertion (A): Imatinib is the first-line treatment for chronic phase CML.<br>Reason (R): Imatinib targets the BCR-ABL1 tyrosine kinase, the product of the Philadelphia chromosome.</span></p>",
      "unique_key": "DT1295288",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295288,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Imatinib specifically inhibits the BCR-ABL1 tyrosine kinase, which is the driver mutation in CML.</li>\r\n<li>This targeted approach has dramatically improved survival rates in CML patients.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501087ef8bbd3-96cb-45b7-b434-9c3dde1cb78a.jpg\">\r\n<p><strong>Key Takeaways: </strong><strong>Imatinib</strong> revolutionized the treatment of CML by targeting the underlying molecular abnormality.</p>\r\n ",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">High-dose cytarabine</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Intrathecal methotrexate</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral mercaptopurine</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Rituximab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 40-year-old patient with Acute Lymphoblastic Leukemia (ALL) is undergoing induction chemotherapy. Which of the following is a critical component of CNS prophylaxis in ALL?</span></p>",
      "unique_key": "DT1295289",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295289,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>CNS prophylaxis is essential in ALL to prevent CNS relapse and commonly involves intrathecal chemotherapy such as methotrexate.</li>\r\n<li>High-dose cytarabine is used in AML regimens but not specifically for CNS prophylaxis in ALL.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong><strong>Intrathecal chemotherapy is a cornerstone of ALL management to prevent CNS involvement</strong>.</p>\r\n ",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased IgM levels</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypogammaglobulinemia</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Monoclonal IgA secretion</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypergammaglobulinemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old man presents with recurrent infections and is diagnosed with CLL. What is the most common immunoglobulin abnormality associated with CLL?</span></p>",
      "unique_key": "DT1295290",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295290,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Hypogammaglobulinemia is common in CLL, leading to an increased risk of infections</strong>.</li>\r\n<li>Other immunoglobulin abnormalities are less commonly seen in CLL.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Immune dysfunction in CLL contributes significantly to morbidity and requires monitoring.</p>\r\n ",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">t(8;21)</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">t(15;17)</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">t(9;22)</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">t(11;14)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25-year-old female with APL presents with severe coagulopathy. Which of the following genetic abnormalities is associated with APL?</span></p>",
      "unique_key": "DT1295291",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295291,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>APL is characterized by the t(15;17) translocation involving the <strong>PML-RARA</strong> fusion gene.</li>\r\n<li>Other translocations are associated with different subtypes of leukemia and lymphomas.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>The t(15;17) translocation in APL is a target for specific therapies like ATRA and arsenic trioxide.</p>\r\n ",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Imatinib</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Gilteritinib</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Venetoclax</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Dasatinib</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old patient with relapsed AML is being considered for a novel therapy. Which of the following agents specifically targets FLT3 mutations in AML?</span></p>",
      "unique_key": "DT1295292",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295292,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Gilteritinib is a tyrosine kinase inhibitor specifically designed to target FLT3 mutations in AML.</li>\r\n<li>Other drugs listed target different pathways, such as BCR-ABL1 in CML.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Targeted therapies are becoming crucial in the management of AML, particularly for specific mutations like FLT3.</p>\r\n ",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute Lymphoblastic Leukemia (ALL)</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute Myeloid Leukemia (AML)</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Myeloid Leukemia (CML)</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Lymphocytic Leukemia (CLL)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old patient presents with gingival hyperplasia, fatigue, and high leukocyte count. Peripheral blood smear shows blasts with Auer rods. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295293",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295293,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Auer rods are specific to AML and not seen in other leukemias.</li>\r\n<li>Gingival hyperplasia is also commonly associated with AML.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>AML presents with specific morphologic features like Auer rods that help differentiate it from other leukemias.</p>\r\n ",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute Lymphoblastic Leukemia (ALL)</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Lymphocytic Leukemia (CLL)</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Myeloid Leukemia (CML)</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Hodgkin Lymphoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 72-year-old patient with lymphocytosis and recurrent infections is found to have smudge cells on peripheral smear. What is the most likely diagnosis?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250108e795e570-7d19-4414-9a1d-5481bbfbf667.jpg\"></span></p>",
      "unique_key": "DT1295294",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295294,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Smudge cells are characteristic of CLL, representing fragile lymphocytes.</li>\r\n<li>These are not seen in ALL, CML, or Hodgkin lymphoma.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Smudge cells on a blood smear are a key diagnostic feature of CLL.</p>\r\n ",
      "correct_choice_id": 102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute Myeloid Leukemia (AML)</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Burkitt Lymphoma</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Diffuse Large B-Cell Lymphoma (DLBCL)</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">T-cell Lymphoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old patient with lymphadenopathy is diagnosed with a B-cell neoplasm. Flow cytometry shows CD19 and CD20 positivity. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295295",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295295,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>CD19 and CD20 positivity is consistent with B-cell neoplasms, particularly DLBCL.</li>\r\n<li>AML is myeloid and lacks these markers, and T-cell lymphomas express different surface markers.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Flow cytometry is essential for classifying lymphomas and identifying specific subtypes based on surface markers.</p>\r\n ",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">A2, B1, C3, D4</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">A1, B2, C3, D4</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">A4, B1, C3, D2</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">A3, B1, C2, D4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the Genetic Abnormality with the Corresponding Leukemia/Lymphoma Subtype:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501088a5018ce-2f85-426c-bfb9-0761b99013e6.jpg\"></span></p>",
      "unique_key": "DT1295297",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295297,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>t(15;17) is characteristic of APL.</li>\r\n<li>t(8;14) is associated with Burkitt Lymphoma.</li>\r\n<li>t(9;22) is the hallmark of CML.</li>\r\n<li>t(11;14) is seen in Mantle Cell Lymphoma.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">A3, B2, C1, D4</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">A1, B2, C3, D4</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">A2, B1, C3, D4</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">A1, B3, C2, D4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the Lymphoma Subtype with its Common Treatment Approach:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010876ccf9a4-cf3b-4f23-bd21-82d6d90dc1a2.jpg\"></span></p>",
      "unique_key": "DT1295299",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295299,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Follicular Lymphoma is commonly treated with Bendamustine and Rituximab.</li>\r\n<li>Hodgkin Lymphoma standard treatment is ABVD.</li>\r\n<li>DLBCL is typically treated with R-CHOP.</li>\r\n<li>Burkitt Lymphoma requires intensive chemotherapy with CNS prophylaxis.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">R-CHOP</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Imatinib</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Ibrutinib</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old man with CLL is being evaluated for treatment initiation. He has symptoms of significant fatigue, night sweats, and rapidly increasing lymphocyte count. Which of the following is the most appropriate first-line treatment option for CLL in this patient?</span></p>",
      "unique_key": "DT1295301",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295301,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Ibrutinib is a first-line treatment for symptomatic CLL and works by inhibiting Bruton's tyrosine kinase (BTK), which is crucial for B-cell proliferation.</li>\r\n<li><strong>R-CHOP is used for DLBCL</strong>, not CLL.</li>\r\n<li><strong>Imatinib is used in CML</strong>.</li>\r\n<li>Methotrexate is used in CNS prophylaxis for ALL.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>BTK inhibitors like Ibrutinib have become standard care for symptomatic CLL.</p>\r\n ",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of tyrosine kinase</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Induction of differentiation of leukemic cells</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">DNA alkylation</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Protein synthesis inhibition</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 34-year-old woman with newly diagnosed Acute Promyelocytic Leukemia (APL) is started on ATRA (all-trans retinoic acid). What is the primary mechanism of action of ATRA in APL?</span></p>",
      "unique_key": "DT1295302",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295302,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>ATRA targets the PML-RARA fusion protein, promoting <strong>differentiation of promyelocytes, which is the hallmark of APL</strong>.</li>\r\n<li>Other mechanisms listed are associated with different classes of drugs.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>ATRA is essential in APL therapy, transforming treatment outcomes by targeting leukemic cell differentiation.</p>\r\n ",
      "correct_choice_id": 152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Diffuse Large B-Cell Lymphoma (DLBCL)</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Lymphocytic Leukemia (CLL)</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Follicular Lymphoma</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Mantle Cell Lymphoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old male presents with lymphadenopathy and elevated white blood cell count. Flow cytometry shows CD5 and CD23 positivity, but negative CD10. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295303",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295303,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>CD5 and CD23 positivity are characteristic of CLL, while the absence of CD10 helps differentiate it from other lymphomas.</li>\r\n<li>DLBCL lacks these markers, and Mantle Cell Lymphoma shows CD5 positivity but not CD23.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Immunophenotyping is critical in differentiating between lymphoid malignancies.</p>\r\n ",
      "correct_choice_id": 162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">T315I</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">JAK2 V617F</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">FLT3-ITD</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">BRAF V600E</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old patient with CML is treated with Imatinib but shows suboptimal response. What mutation is commonly associated with resistance to Imatinib in CML?</span></p>",
      "unique_key": "DT1295305",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295305,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The <strong>T315I mutation in the BCR-ABL1 gene confers resistance to Imatinib and other TKIs except for newer agents like Ponatinib.</strong></li>\r\n<li>JAK2 is seen in myeloproliferative disorders, FLT3-ITD in AML, and BRAF V600E in melanoma.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Identification of T315I mutation guides the shift to alternative TKIs such as Ponatinib in resistant CML.</p>\r\n ",
      "correct_choice_id": 171,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Venetoclax</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Gilteritinib</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Dasatinib</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Rituximab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old woman with AML is found to have FLT3-ITD mutation. Which of the following therapies specifically targets this mutation?</span></p>",
      "unique_key": "DT1295306",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295306,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Gilteritinib is specifically designed to inhibit FLT3 mutations</strong>, including ITD and TKD variants, offering targeted treatment in AML.</li>\r\n<li><strong>Venetoclax targets BCL2, Dasatinib targets BCR-ABL1, and Rituximab targets CD20.</strong></li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Targeted therapies have transformed AML management, especially for high-risk genetic mutations like FLT3.</p>\r\n ",
      "correct_choice_id": 182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Rituximab</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Tyrosine kinase inhibitor (e.g., Imatinib)</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Lenalidomide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old male with ALL is found to have the Philadelphia chromosome. Which additional therapy should be considered in his treatment regimen?</span></p>",
      "unique_key": "DT1295307",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295307,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The presence of the Philadelphia chromosome (BCR-ABL1) in ALL indicates the need for TKIs like <strong>Imatinib in combination with standard chemotherapy</strong>.</li>\r\n<li>Rituximab targets CD20, Methotrexate is used in CNS prophylaxis, and Lenalidomide is used in multiple myeloma.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>TKIs are essential in managing Philadelphia chromosome-positive ALL, significantly improving outcomes.</p>\r\n ",
      "correct_choice_id": 192,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydroxyurea</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">High-dose steroids</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Second-generation TKIs (e.g., Dasatinib, Nilotinib)</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">R-CHOP</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old patient presents with symptoms of fever, fatigue, and splenomegaly. His complete blood count shows leukocytosis with increased basophils. The patient is diagnosed with CML in the accelerated phase. What is the first-line treatment for this phase?</span></p>",
      "unique_key": "DT1295309",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295309,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Second-generation TKIs are the preferred treatment for accelerated-phase CML due to their enhanced efficacy compared to Imatinib.</li>\r\n<li>Hydroxyurea is used for cytoreduction but is not the primary treatment. Steroids and R-CHOP are not indicated.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Managing accelerated-phase CML requires more potent TKIs to control disease progression effectively.</p>\r\n ",
      "correct_choice_id": 203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug toxicity</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Immune-mediated destruction of red cells</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Bone marrow infiltration</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic blood loss</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 70-year-old patient with CLL presents with hemolytic anemia. What is the most likely mechanism behind this complication?</span></p>",
      "unique_key": "DT1295310",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295310,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Hemolytic anemia in CLL is often immune-mediated, with autoantibodies targeting red blood cells.</li>\r\n<li>Drug toxicity, marrow infiltration, and chronic blood loss do not commonly present as hemolysis in CLL.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Autoimmune complications are frequent in CLL and contribute significantly to morbidity.</p>\r\n ",
      "correct_choice_id": 212,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Good prognosis with standard chemotherapy</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Intermediate prognosis requiring careful monitoring</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Poor prognosis with high risk of relapse</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">No impact on prognosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old woman with newly diagnosed AML is found to have a complex karyotype and TP53 mutation. What does this indicate about her prognosis?</span></p>",
      "unique_key": "DT1295312",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295312,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Complex karyotypes and TP53 mutations are associated with poor outcomes and high relapse rates in AML, often requiring more aggressive or alternative treatment strategies.</li>\r\n</ul>\r\n<p><strong>Key Takeaways: </strong>Genetic findings like TP53 mutation significantly impact the prognosis and guide therapy decisions in AML.</p>\r\n ",
      "correct_choice_id": 223,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">A1, B2, C3, D4</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">A3, B2, C1, D4</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">A1, B2, C4, D3</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">A2, B1, C3, D4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the Chemotherapy Regimen with its Corresponding Indication:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250108d3f2e573-4e26-4ed5-9f78-b25994c5ac51.jpg\"></span></p>",
      "unique_key": "DT1295314",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295314,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>R-CHOP is used for DLBCL.</li>\r\n<li>ABVD is the standard for Hodgkin Lymphoma.</li>\r\n<li>Hyper-CVAD is used in ALL, especially high-risk cases.</li>\r\n<li>FCR is a common regimen in the treatment of CLL.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 231,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">A1, B2, C3, D4</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">A3, B2, C1, D4</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">A1, B2, C4, D3</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">A2, B1, C3, D4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the Prognostic Marker with Its Associated Leukemia:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250108595a0944-2eed-483d-a756-2f6583136ce4.jpg\"></span></p>",
      "unique_key": "DT1295315",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295315,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>BCR-ABL1 is seen in CML.</li>\r\n<li>FLT3-ITD mutation is associated with poor prognosis in AML.</li>\r\n<li>CD19 and CD10 are markers in ALL.</li>\r\n<li>del(13q) is associated with a favorable prognosis in CLL.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501084153bf39-7451-4d68-b53e-18c3ecd69467.jpg\">\r\n ",
      "correct_choice_id": 241,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}